TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16003508

Group type: EXPERIMENTAL
Intervention: MRI findings in AC shoulders with IV Gd-chelate
Number of subjects: 26

Group type: COMPARATOR
Intervention: MRI findings in healthy shoulders (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Interobserver reliability for axillary recess
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Interobserver reliability for rotator interval
Number of subjects: 26
Study: 12558609

Group type: EXPERIMENTAL
Intervention: Racemic salbutamol inhaled three times during a 6-h period
Number of subjects: 15

Group type: COMPARATOR
Intervention: No drug treatment (control)
Number of subjects: 15
Study: 10053176

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 to 40 mg per day) with possible addition of enalapril (5 to 20 mg per day) or hydrochlorothiazide (12.5 to 25 mg per day) or both, titrated to reduce systolic blood pressure by at least 20 mm Hg and to less than 150 mm Hg.
Number of subjects: 4695
Study: 8909665

Group type: EXPERIMENTAL
Intervention: PHD+IAT
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PHD+IAT+HA
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 1681343

Group type: EXPERIMENTAL
Intervention: Induced sputum (ultrasonic nebuliser)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ordinary sputum (expectoration)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 67
Study: 6347014

Group type: EXPERIMENTAL
Intervention: Op-Site sutureless skin closures
Number of subjects: 55

Group type: COMPARATOR
Intervention: Continuous nylon sutures
Number of subjects: 55
Study: 30952386

Group type: EXPERIMENTAL
Intervention: Combined intra‐ and postoperative tranexamic acid (TXA) treatment
Number of subjects: 30
Study: 29394003

Group type: EXPERIMENTAL
Intervention: Nicotine patch with replacement PIB adhesive (test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine patch with previously used PIB adhesive (reference)
Number of subjects: 0
Study: 26494529

Group type: EXPERIMENTAL
Intervention: Ventricular Assist Device (VAD) implantation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) in Fontan circulation with systolic dysfunction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Right Ventricular Assist Device (RVAD) in Fontan circulation with systolic dysfunction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) in Fontan circulation with diastolic dysfunction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Right Ventricular Assist Device (RVAD) in Fontan circulation with diastolic dysfunction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Right Ventricular Assist Device (RVAD) with pulmonary vascular resistance increment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ventricular Assist Device (VAD) speed adjustment
Number of subjects: 30
Study: 24256372

Group type: EXPERIMENTAL
Intervention: HMG
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clomiphene citrate (C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate + HMG (CH)
Number of subjects: 90
Study: 22131101

Group type: EXPERIMENTAL
Intervention: Paquinimod (4.5 mg/day and 6.0 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paquinimod (up to 3.0 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paquinimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone and mycophenolate mofetil
Number of subjects: 0
Study: 21055907

Group type: EXPERIMENTAL
Intervention: Immediate release alprazolam, extended release alprazolam, clonazepam
Number of subjects: 6
Study: 17414726

Group type: EXPERIMENTAL
Intervention: Video-based online training course
Number of subjects: 50
Study: 15680718

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevalent anemia at randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incident anemia after randomization
Number of subjects: 0
Study: 12067168

Group type: EXPERIMENTAL
Intervention: Combined antibiotics (neomycin and metronidazole orally)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Systemic antibiotics (placebo)
Number of subjects: 215
Study: 10508004

Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg moxifloxacin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 400 mg moxifloxacin over 60 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single doses of 400 mg moxifloxacin
Number of subjects: 12
Study: 7861488

Group type: EXPERIMENTAL
Intervention: Dornier HM3 lithotriptor
Number of subjects: 13864

Group type: COMPARATOR
Intervention: Medstone STS lithotriptor
Number of subjects: 13864
Study: 2116622

Group type: EXPERIMENTAL
Intervention: Immediate coronary angioplasty following successful thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed elective angioplasty
Number of subjects: 0
Study: 7031582

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control
Number of subjects: 258
Study: 31981412

Group type: EXPERIMENTAL
Intervention: Standardized meal (3,600 kJ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 10
Study: 31272285

Group type: EXPERIMENTAL
Intervention: Transfection of miR‐145‐5p inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: High glucose group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FGF5 knockdown
Number of subjects: 0
Study: 28846584

Group type: EXPERIMENTAL
Intervention: Expectation manipulation intervention
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Preoperative interventions (Expectation manipulation and Supportive therapy)
Number of subjects: 124
Study: 26782835

Group type: EXPERIMENTAL
Intervention: Intense hypertension treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihypertensive agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 24421302

Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO) 25 mg and Pioglitazone (PIO) 30 mg daily
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO) 25 mg daily monotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 71
Study: 22782482

Group type: COMPARATOR
Intervention: 10 Hz TMS stimulation (study 1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1 Hz TMS stimulation (study 1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1 Hz TMS stimulation (study 2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 5 Hz TMS stimulation (study 2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 10 Hz TMS stimulation (study 2)
Number of subjects: 64
Study: 18727140

Group type: EXPERIMENTAL
Intervention: Informal caregiving time assessment using a German adaptation of the Resource Utilization in Dementia (RUD) questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclusion of time from all informal caregivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interviewing the primary informal caregiver
Number of subjects: 0
Study: 17156824

Group type: EXPERIMENTAL
Intervention: Low dose HT (1 mg 17 beta‐estradiol + 0.5 mg norethisterone acetate)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Conventional dose HT (2 mg 17 beta‐estradiol + 1 mg NETA)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 202
Study: 15151621

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 21
Study: 12484051

Group type: EXPERIMENTAL
Intervention: PHAI (5-FU: 500 mg/body/week for 50 cycles) plus oral UFT-E (400 mg/body/day for 24 months)
Number of subjects: 49

Group type: COMPARATOR
Intervention: UFT-E alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PHAI
Number of subjects: 49
Study: 9849245

Group type: EXPERIMENTAL
Intervention: Arglaes film dressing (a transparent dressing containing silver ions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Tegaderm (a transparent polyurethane dressing)
Number of subjects: 31
Study: 7926076

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (60 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (40 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 2684174

Group type: EXPERIMENTAL
Intervention: 200 micrograms of muroctasin for 6 days post-chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 micrograms of muroctasin for 6 days post-chemotherapy
Number of subjects: 0
Study: 786689

Group type: EXPERIMENTAL
Intervention: Propranolol (640 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Practolol (1600 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chlorthalidone (100 mg 3 times weekly)
Number of subjects: 28
Study: 31157556

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges (three lozenges per day for two weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo lozenges (three lozenges per day for two weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 64
Study: 28578646

Group type: COMPARATOR
Intervention: Ropivacaine 0.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with 100 mcg clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with 4 mg dexamethasone and 100 mcg clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with 4 mg dexamethasone
Number of subjects: 0
Study: 26072017

Group type: EXPERIMENTAL
Intervention: M72/AS01E vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23477886

Group type: EXPERIMENTAL
Intervention: Coated seeds
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular seeds
Number of subjects: 40
Study: 21900439

Group type: EXPERIMENTAL
Intervention: Monetary compensation ($150)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Continuing medical education (CME) credits (5 hours)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Overall participation (all physicians approached)
Number of subjects: 211
Study: 19563186

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with oral administration of Flunarizine Hydrochloride vacuity capsules, thrice each week for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of Flunarizine Hydrochloride capsules combined with acupuncture at placebo-points, thrice each week for 4 weeks.
Number of subjects: 60
Study: 16889569

Group type: EXPERIMENTAL
Intervention: TCC locked with cefotaxime (10 mg/mL) and heparin (5000 U/mL)
Number of subjects: 113

Group type: COMPARATOR
Intervention: TCC with heparin (5000 U/mL) alone
Number of subjects: 113
Study: 15351163

Group type: EXPERIMENTAL
Intervention: Abciximab (stenting plus abciximab)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control (stenting without abciximab)
Number of subjects: 401
Study: 11137279

Group type: EXPERIMENTAL
Intervention: 12 h/week day hospital program (DH12)
Number of subjects: 94

Group type: COMPARATOR
Intervention: 6 h/week outpatient program (OP6)
Number of subjects: 94
Study: 9425400

Group type: EXPERIMENTAL
Intervention: GHRH infusion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GHRP-2 infusion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-2 infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 26
Study: 8505663

Group type: EXPERIMENTAL
Intervention: Albendazole (600 mg single dose)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 3685573

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Oxaprotiline (OT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) and Oxaprotiline (OT)
Number of subjects: 59
Study: 29669536

Group type: EXPERIMENTAL
Intervention: Caregiver-inclusive assistive technology intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 90
Study: 26603017

Group type: EXPERIMENTAL
Intervention: Heterogeneous dual-task training
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Homogeneous dual-task training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Active placebo (computer lessons)
Number of subjects: 58
Study: 25588130

Group type: EXPERIMENTAL
Intervention: Water-soluble vitamins
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23392532

Group type: EXPERIMENTAL
Intervention: Experimental gamble (high probability of winning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-risk control gamble
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental gamble (actual outcome presented)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipation of reward
Number of subjects: 0
Study: 21393376

Group type: EXPERIMENTAL
Intervention: Radio Diaries program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Radio Diaries program followed by group discussion
Number of subjects: 300
Study: 18462303

Group type: EXPERIMENTAL
Intervention: Compeed cold sore patch (CSP)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Acyclovir cream 5%
Number of subjects: 351
Study: 17100814

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pubovaginal sling
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 14979215

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11234463

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 9252517

Group type: EXPERIMENTAL
Intervention: loxiglumide (CCK-A antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 12
Study: 1492262

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (1.0 g/0.5 g) with probenecid (1 g)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Ceftriaxone (0.25 g)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam with probenecid
Number of subjects: 274

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 274
Study: 3986258

Group type: EXPERIMENTAL
Intervention: Unilateral nondominant ECT
Number of subjects: 58

Group type: COMPARATOR
Intervention: Bilateral ECT
Number of subjects: 58
Study: 30871496

Group type: EXPERIMENTAL
Intervention: DHAPP + SLDPQ
Number of subjects: 109

Group type: COMPARATOR
Intervention: DHAPP alone
Number of subjects: 109
Study: 29380728

Group type: EXPERIMENTAL
Intervention: Everolimus (1.5 mg twice daily)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Tacrolimus (control group)
Number of subjects: 194
Study: 27550305

Group type: EXPERIMENTAL
Intervention: Active lifestyle modification (supervised intervention by two dietitians over 6 months)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Passive lifestyle modification (leaflet guidance only over 6 months)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Active lifestyle modification
Number of subjects: 130

Group type: COMPARATOR
Intervention: Passive lifestyle modification
Number of subjects: 130
Study: 24632146

Group type: EXPERIMENTAL
Intervention: Posterior metal-free polymer crowns with glass-fibre framework (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Posterior metal-free polymer crowns without framework (group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metal-ceramic crowns (control group)
Number of subjects: 120
Study: 22699194

Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration training
Number of subjects: 38

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 38
Study: 20953593

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg (4.86 μmol)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 17114888

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) in patients with active acromegaly (AA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT) in group A controls
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT) in patients with growth hormone deficiency (GHD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT) in group B controls
Number of subjects: 41
Study: 16258579

Group type: EXPERIMENTAL
Intervention: EMG-biofeedback training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Classical exercise program
Number of subjects: 40
Study: 12412171

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen (Arm Y: every 4 weeks; Arm Z: every 3 weeks) consisting of epirubicin (240 mg/m(2)), bleomycin (60 mg/m(2)), vinblastine (20 mg/m(2)), vincristine (4 mg/m(2)), cyclophosphamide (4000 mg/m(2)), etoposide (900 mg/m(2)), methotrexate (180 mg/m(2)), methylprednisolone (1500 mg/m(2)) over 12 weeks followed by extended-field lymph node irradiation (involved areas, 40 grays [Gy]; noninvolved areas, 30 Gy).
Number of subjects: 162

Group type: COMPARATOR
Intervention: Chemotherapy regimen (Arm Z: every 3 weeks) consisting of epirubicin (240 mg/m(2)), bleomycin (60 mg/m(2)), vinblastine (20 mg/m(2)), vincristine (4 mg/m(2)), cyclophosphamide (4000 mg/m(2)), etoposide (900 mg/m(2)), methotrexate (180 mg/m(2)), methylprednisolone (1500 mg/m(2)) over 12 weeks followed by extended-field lymph node irradiation (involved areas, 40 grays [Gy]; noninvolved areas, 30 Gy).
Number of subjects: 162
Study: 10807190

Group type: EXPERIMENTAL
Intervention: Combination tablet regimen (lamivudine 150 mg/zidovudine 300 mg twice daily plus a protease inhibitor)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional regimen (150 mg lamivudine twice daily, 600 mg zidovudine daily, and a protease inhibitor)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Combination tablet regimen
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional regimen
Number of subjects: 223
Study: 8794812

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (estradiol valerate, 2 mg daily, n = 6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 11
Study: 1536438

Group type: EXPERIMENTAL
Intervention: Autologous blood (group 2, n = 14)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intra- and postoperative autologous fresh frozen plasma (FFP) (group 3, n = 16)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Homologous blood (control group, group 1, n = 12)
Number of subjects: 42
Study: 6465489

Group type: EXPERIMENTAL
Intervention: Oral controlled-release morphine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 0
Study: 31707858

Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking with simultaneous intrastromal corneal ring segment implantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Corneal collagen cross-linking alone
Number of subjects: 30
Study: 30835744

Group type: EXPERIMENTAL
Intervention: Patient-Specific Functional Scale (PSFS)
Number of subjects: 86
Study: 30463770

Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy (PC)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Interval cholecystectomy (CCY)
Number of subjects: 145
Study: 26715577

Group type: EXPERIMENTAL
Intervention: Copper (Cu) plus ascorbic acid (AA) at 4/1 Cu/Fe molar ratio
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Copper (Cu) plus ascorbic acid (AA) at 6/1 Cu/Fe molar ratio
Number of subjects: 14

Group type: COMPARATOR
Intervention: Iron alone (Control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Copper (Cu) plus ascorbic acid (AA) at 8/1 Cu/Fe molar ratio
Number of subjects: 14
Study: 24559810

Group type: EXPERIMENTAL
Intervention: Ginger powder supplementation (3 one-gram capsules daily for 8 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (3 one-gram microcrystalline-containing capsules daily for 8 weeks)
Number of subjects: 88
Study: 22934442

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 0
Study: 20004278

Group type: EXPERIMENTAL
Intervention: Polymer alone
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Polymer/SLS
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 17921390

Group type: EXPERIMENTAL
Intervention: 3 mg Zn/d as a supplement
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 16173138

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (12.5 mmol daily for 6 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Spironolactone treatment
Number of subjects: 59
Study: 12549635

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard treatment (without Tamsulosin)
Number of subjects: 104
Study: 10553163

Group type: EXPERIMENTAL
Intervention: IL‐3 (10 microg/kg/day, s.c., day 1‐5) followed by G‐CSF (5 microg/kg/day, day 6‐8)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IL‐3 (10 microg/kg/day, s.c., day 1‐5) followed by GM‐CSF (5 microg/kg/day, day 6‐8)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IL‐3+G‐CSF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IL‐3+GM‐CSF
Number of subjects: 50
Study: 8821120

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blackcurrant oil supplementation
Number of subjects: 0
Study: 31117905

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: History of moderate to severe TBI
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PTSD status
Number of subjects: 62
Study: 29324430

Group type: EXPERIMENTAL
Intervention: Disposable, high-fluid capacity underpad
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonpermeable, reusable containment products
Number of subjects: 40